Co-Authors
This is a "connection" page, showing publications co-authored by DANIEL J BOOSER and SHARON HERMES GIORDANO.
Connection Strength
0.214
-
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 2002 Nov; 8(11):3360-8.
Score: 0.056
-
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112.
Score: 0.044
-
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-?. Invest New Drugs. 2018 12; 36(6):1103-1109.
Score: 0.042
-
Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 2014 Jul 01; 120(13):1932-8.
Score: 0.031
-
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer. 2012 May 01; 118(9):2378-84.
Score: 0.026
-
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 01; 23(16):3676-85.
Score: 0.016